This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma	MicroRNA-155 (miR-155)	<p>Mouse studies suggest inhibiting miR-155 with locked nucleic acids (LNAs) could help treat low-grade B cell lymphomas, such as Waldenström's macroglobulinemia (WM). In a mouse xenograft model of WM, LNA-mediated inhibition of miR-155 decreased tumor growth compared with no miR-155 inhibition. In a coculture of a human WM cell line and primary WM bone marrow stromal cells, LNA-mediated inhibition of miR-155 decreased proliferation. Researchers did not disclose next steps, which could include evaluating the miR-155-targeting LNAs in additional B cell lymphoma subtypes.</p> <p><i>SciBX</i> 5(30); doi:10.1038/scibx.2012.779 Published online Aug. 2, 2012</p>	Patent and licensing status undisclosed	<p>Zhang, Y. <i>et al. Blood</i>; published online July 13, 2012; doi:10.1182/blood-2012-02-410647 Contact: Irene M. Ghobrial, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Mass. e-mail: irene_ghobrial@dfci.harvard.edu</p>